Plasma von Willebrand Factor and ADAMTS13 Interact With APOE ‐ε4 in Predicting Longitudinal Brain Atrophy and Cognitive Decline Over a 9‐Year Follow‐Up

Key Points

• The research aims to investigate how plasma VWF and ADAMTS13 relate to brain atrophy and cognitive decline, particularly in the presence of the APOE-ε4 allele.
• Longitudinal follow-up over 9 years
• Assessment of brain atrophy and cognitive decline
• Comparison of plasma VWF and ADAMTS13 levels
• ADAMTS13 is suggested as a promising biomarker for brain aging outcomes.
• VWF's effectiveness as a biomarker varies depending on the presence of the APOE-ε4 allele.